Coagulation Monitoring

Anesthesiology Clinics of North America

Volumn 24, Issue 4, 2006, Pages 839-856

  Rochon, Antoine G ^a   Shore Lesserson, Linda ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; PROTAMINE SULFATE; STREPTOKINASE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOPLASTIN; TICLOPIDINE; TIROFIBAN; WARFARIN;

BLOOD CLOTTING; BLOOD CLOTTING TIME; DRUG MEGADOSE; FIBRINOLYSIS; HEART DISEASE; HEMOSTASIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOSIS;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; FIBRINOLYSIS; HUMANS; PLATELET FUNCTION TESTS;

EID: 33845321732     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2006.08.003     Document Type: Review

References (102)

1. Glesen P.L., and Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 26 (2000) 379-384
2. Roberts H.R., Monroe D.M., and Escobar M.A. Current concepts of hemostasis. Anesthesiology 100 (2004) 722-730
3. Thompson E.A., and Salem H.H. Inhibition by human thrombomodulin of factor Xa-mediated cleavage of prothrombin. J Clin Invest 78 1 (1986) 13-17
4. Cines D.B., Polack E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3627-3661
5. Esmon C.T., and Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 6 5 (1995) 259-268
6. Broze Jr. G.J. Tissue factor pathway inhibitor. Thromb Haemost 74 1 (1990) 90-93
7. Marcum J.A., and Rosenberg R.D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 23 8 (1984) 1730-1737
8. Davie E.W., and Ratnoff O.D. Waterfall sequence for intrinsic blood clotting. Science 164 (1964) 1310-1312
9. Eika C., Havig O., and Godal H.C. The value of preoperative haemostatic screening. Scand J Haematol 21 (1978) 349-354
10. Kaplan E.B., Sheiner L.B., and Boeckmann A.J. The usefulness of preoperative laboratory screening. JAMA 253 (1985) 3576-3581
11. Rodgers R.P., and Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 21 (1995) 21-26
12. Jurk K., and Kehrel B.E. Platelets: physiology and biochemistry. Semin Thromb Hemost 31 4 (2005) 381-392
13. Shattil S.J., Ginsberg M.H., and Brugge J.S. Adhesive signaling in platelets. Curr Opin Cell Biol 6 (1994) 695-704
14. Fox J.E. The platelet cytoskeleton. Thromb Haemost 70 (1993) 884-893
15. Phillips D.R., Law D., and Scarborough R.M. Glycoprotein IIb-IIIa in platelet aggregation: an emerging target for the prevention of acute coronary thrombotic occlusions. Arch Pathol Lab Med 122 (1998) 811-812
16. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 (2002) 1381-1389
17. Samama C.M., Djoudi R., Lecompte T., et al. Perioperative platelet transfusion: recommendations of the Agence française de sécurité sanitaire des produits de santé (AFSSaPS) 2003. Can J Anesth 52 (2005) 30-37
18. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 17 (1957) 237-246 [in English]
19. Reich D.L., Yanakakis M.J., Vela-Cantos F.P., et al. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg 77 (1993) 673-679
20. Reiner J.S., Coyne K.S., Lundergan C.F., et al. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32 1 (1994) 49-52
21. Bain B., Forster T., and Sleigh B. Heparin and the activated partial thromboplastin time - a difference between the in vitro and in vivo effects and implications for the therapeutic range. Am J Clin Pathol 74 (1980) 668-673
22. Samama C.M., Quezada R., Riou B., et al. Intraoperative measurement of activated partial thromboplastin time and prothrombin time with a new compact monitor. Acta Anaesthesiol Scand 38 (1994) 232-237
23. Nuttall G.A., Oliver W.C., Beynen F.M., et al. Determination of normal versus abnormal activated partial thromboplastin time and prothrombin time after cardiopulmonary bypass. [see comments]. J Cardiothorac Vasc Anesth 9 (1995) 355-361
24. Despotis G.J., Santoro S.A., Spitznagel E., et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 107 (1994) 271-279
25. Despotis G.J., Grishaber J.E., and Goodnough L.T. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery. [see comments]. Transfusion 34 (1994) 290-296
26. Muller N., Popov-Cenic S., Buttner W., et al. Studies of fibrinolytic and coagulation factors during open heart surgery. II. Postoperative bleeding tendency and changes in the coagulation system. Thromb Res 7 (1975) 589-598
27. Umlas J. Fibrinolysis and disseminated intravascular coagulation in open heart surgery. Transfusion 16 (1976) 460-463
28. Jaberi M., Bell W.R., and Benson D.W. Control of heparin therapy in open-heart surgery. J Thorac Cardiovasc Surg 67 (1974) 133-141
29. Aggarwal A., Sobel B.E., and Schneider D.J. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 13 (2002) 161-165
30. Doggrell S. Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?. Expert Opin Pharmacother 4 8 (2003) 1431-1433
31. Weitz J.I., and Crowther M.A. New anticoagulants: current status and future potential. Am J Cardiovasc Drugs 3 3 (2003) 201-209
32. Dyke C.M., Smedira N.G., et al. A comparison of bivalirudin to heparin with protamine reversal inpatients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131 3 (2006) 533-539
33. Zucker M.L., Koster A., et al. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol 37 4 (2005) 364-368
34. Metz S., and Keats A.S. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 49 (1990) 440-444
35. Culliford A.T., Gitel S.N., Starr N., et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 193 (1981) 105-111
36. Wang J.S., Lin C.Y., and Karp R.B. Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients. Anesth Analg 79 (1994) 9-13
37. Wang J.S., Lin C.Y., Hung W.T., et al. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 77 (1992) 1080-1084
38. Ammar T., Scudder L.E., and Coller B.S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. [see comments]. Circulation 95 (1997) 614-617
39. Gravlee G.P., Whitaker C.L., Mark L.J., et al. Baseline activated coagulation time should be measured after surgical incision. Anesth Analg 71 (1990) 549-553
40. Despotis G.J., Summerfield A.L., Joist J.H., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108 (1994) 1076-1082
41. Martindale S.J., Shayevitz J.R., and D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 10 (1996) 458-463
42. Despotis G.J., Joist J.H., Hogue Jr. C.W., et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 76 (1996) 902-908
43. Gravlee G.P., Haddon W.S., Rothberger H.K., et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 99 (1990) 518-527
44. Gravlee G.P., Rogers A.T., Dudas L.M., et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 76 (1992) 393-401
45. Rochon A.G., Stone M.E., et al. A comparison of two heparin management devices for cardiopulmonary bypass. Anesthesiology 101 (2005) A-393
46. Wang J.S., Lin C.Y., and Karp R.B. Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients. Anesth Analg 79 (1994) 9-13
47. Tabuchi N., Njo T.L., Tigchelaar I., et al. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Ann Thorac Surg 58 (1994) 774-777
48. Shore-Lesserson L., Manspeizer H.E., Bolastig M., et al. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. Anesth Analg 90 (2000) 813-818
49. Jobes D.R., Aitken G.L., and Shaffer G.W. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 110 (1995) 36-45
50. Despotis G.J., Joist J.H., Hogue Jr. C.W., et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. [see comments]. J Thorac Cardiovasc Surg 110 (1995) 46-54
51. Shore-Lesserson L., Reich D.L., and DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. [see comments]. Can J Anaesth 45 (1998) 10-18
52. Jobes D.R., Aitken G.L., and Shaffer G.W. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 110 (1995) 36-45
53. Adelman B., Michelson A.D., Loscalzo J., et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 65 (1985) 32-40
54. Michelson A.D., and Barnard M.R. Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood 70 (1987) 1673-1678
55. Michelson A.D., and Barnard M.R. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood 76 (1990) 2005-2010
56. Rohrer M.J., Kestin A.S., Ellis P.A., et al. High-dose heparin suppresses platelet alpha granule secretion. J Vasc Surg 15 (1992) 1000-1008 [discussion 1008-9]
57. Kestin A.S., Valeri C.R., Khuri S.F., et al. The platelet function defect of cardiopulmonary bypass. [see comments]. Blood 82 (1993) 107-117
58. John L.C., Rees G.M., and Kovacs I.B. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 55 (1993) 1175-1179
59. John L.C., Rees G.M., and Kovacs I.B. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 105 (1993) 816-822
60. Michelson A.D., MacGregor H., Barnard M.R., et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 71 (1994) 633-640
61. Khuri S.F., Valeri C.R., Loscalzo J., et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. [see comments]. Ann Thorac Surg 60 (1995) 1008-1014
62. Steinhubl S.R., Kottke-Marchant K., Moliterno D.J., et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 100 (1999) 1977-1982
63. Steinhubl S.R., Ellis S.G., Wolski K., et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 103 (2001) 1403-1409
64. Bertrand M.E., Rupprecht H.J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
65. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point of care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multi-center study. Circulation 103 (2001) 2572-2578
66. Barragan P., Bouvier J., Roquebert P., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-303
67. Lefkovits J., Ivanhoe R.J., Califf R.M., et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 77 (1996) 1045-1051
68. Brown D.L., Fann C.S., and Chang C.J. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 87 (2001) 537-541
69. Tuman K.J., Spiess B.D., McCarthy R.J., et al. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 69 (1989) 69-75
70. Tuman K.J., McCarthy R.J., Djuric M., et al. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 8 (1994) 144-149
71. Nuttall G.A., Oliver W.C., Ereth M.H., et al. Coagulation tests predict bleeding after cardiopulmonary bypass. [see comments]. J Cardiothorac Vasc Anesth 11 (1997) 815-823
72. Greilich P.E., Alving B.M., O'Neill K.L., et al. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth Analg 84 (1997) 31-38
73. Cherng Y.G., Chao A., Shih R.L., et al. Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Acta Anaesthesiol Sin 36 (1998) 179-186
74. Mousa S.A., Bozarth J.M., Seiffert D., et al. Using thromboelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Blood Coagul Fibrinolysis 16 (2005) 165-171
75. Spiess B.D., Gillies B.S., Chandler W., et al. Changes in transfusion therapy and re-exploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 9 (1995) 168-173
76. Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transplantation. [see comments]. Liver Transpl Surg 3 (1997) 655-659
77. Kang Y. Coagulation and liver transplantation: current concepts. Liver Transpl Surg 3 (1997) 465-467
78. Lesserson L., Manspeizer H.E., DePerio M., et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 88 (1999) 312-319
79. Nuttall G.A., Oliver W.C., Santrach P.J., et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 94 (2001) 773-781 [discussion 5A-6A]
80. Mousa S.A., Khurana S., and Forsythe M.S. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 20 (2000) 1162-1167
81. Kettner S.C., Panzer O.P., Kozek S.A., et al. Use of abciximab-modified thromboelastography in patients undergoing cardiac surgery. Anesth Analg 89 (1999) 580-584
82. Craft R.M., Chavez J.J., Bresse S.J., et al. A novel modification of the Thromboelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 143 5 (2004) 301-309
83. Bode A.P., and Lust R.M. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity. Thromb Res 73 (1994) 285-300
84. Coller B.S., Folts J.D., Scudder L.E., et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68 (1986) 783-786
85. Coller B.S., Lang D., and Scudder L.E. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 95 (1997) 860-867
86. Smith J.W., Steinhubl S.R., Lincoff A.M., et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
87. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point of care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multi-center study. Circulation 103 (2001) 2572-2578
88. Serebruany V.L., Malinin A.I., Ziai W., et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke. Stroke 36 (2005) 2289-2292
89. Kovacs I.B., Mayou S.C., and Kirby J.D. Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: lack of antiplatelet effect but risk of thromboembolism. [see comments]. Am J Med 90 (1991) 41-46
90. John L.C., Rees G.M., and Kovacs I.B. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 55 (1993) 1175-1179
91. Ikarugi H., Taka T., Nakajima S., et al. Norepinephrine, but not epinephrine, enhances platelet reactivity and coagulation after exercise in humans. J Appl Physiol 86 (1999) 133-138
92. Fricke W., Kouides P., Kessler C., et al. A multi-center clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2 (2004) 763-768
93. Griffin M.J., Rinder H.M., Smith B.R., et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 93 (2001) 20-27
94. Kundu S.K., Heilmann E.J., Sio R., et al. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 21 (1995) 106-112
95. Mammen E.F., Comp P.C., Gosselin R., et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24 (1998) 195-202
96. Wahba A., Sander S., and Birnbaum D.E. Are in vitro platelet function tests useful in predicting blood loss following open-heart surgery?. Thorac Cardiovasc Surg 46 (1998) 228-231
97. Slaughter T.F., Sreeram G., Sharma A.D., et al. Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 12 (2001) 85-93
98. Lasne D., Fiemeyer A., Chatellier G., et al. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft. Thromb Haemost 84 (2000) 794-799
99. Carville D.G., Schleckser P.A., Guyer K.E., et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 30 (1998) 171-177
100. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
101. Craft R.M., Chavez J.J., Snider C.C., et al. Comparison of modified Thromboelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 145 (2005) 309-315
102. Ray M.J., Hawson G.A., Just S.J., et al. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 57 (1994) 981-986